Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

This study will test whether the combination of radiation and Dostarlimab is an effective treatment for women with MMR-D/MSI-H endometrial cancer who have recently undergone surgery.

Trial Details

NCT ID
NCT04774419
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Intensity modulated radiation therapy (IMRT)
  • Dostarlimab
  • Hypofractionated IMRT
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Age 18 years or older
  • ECOG performance status 0-1
  • Endometrial cancer: all histologies (submission of pathology report is required for all patients who underwent surgery outside of MSK)
  • MMR-D or MSI-H or POLE-mutated (submission of report\[s\] required for. patients who underwent testing outside of MSK POLE-mutated endometrial canc…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →